AbbVie's Phase 2 study of ABBV-466, which combines Skyrizi with trosunilimab to target two separate drivers of Crohn's inflammation, met its primary endpoint. At week 24, 40.5% of patients on the combination reached endoscopic remission, versus 22.4% on Skyrizi alone and 20% on trosunilimab alone, while serious adverse events occurred in 10.4% of the combination group, compared with 9.6% for Skyrizi and 9% for trosunilimab. BMO Capital Markets and RBC Capital Markets analysts viewed the results positively. The author, noting that Skyrizi and Rinvoq generated $17.5 billion and $8.3 billion in 2025, predicts ABBV-466 could become AbbVie's next blockbuster, while acknowledging that a Phase 3 program and a multi-year approval path still lie ahead.
Summary written by Upside AI from the original article. Read the source for full details.
Read the original on Yahoo Finance ↗
Keywords
AbbViepharmaceuticalsclinical trialshealthcare
Open a keyword to see other news on the same topic.
Related news
- Where Will CRISPR Therapeutics Stock Be in 2030?
Shares of CRISPR Therapeutics have fallen about 47% since mid-October 2021, while the S&P 500 has gained almost 73% as of writing, despite clinical and regulatory progress over the past five years. Casgevy, developed with Vertex Pharmaceuticals, was approved in 2023 and early 2024 for transfusion-dependent beta-thalassemia and sickle cell disease, making it the company's first commercial product and the first approved CRISPR-based gene-editing therapy. Other candidates include CTX310, aimed at lowering LDL cholesterol and triglycerides, where Phase 1 data showed significant decreases in both; zugo-cel for autoimmune diseases and blood cancers; and CTX611, an anticoagulant that could be given twice a year. Casgevy's label now covers patients as young as two, adding about 5,500 U.S. patients at $2.2 million per treatment course. The article warns of possible clinical failures and the costly, one-time nature of many gene-editing therapies, which makes profitability uncertain.
- Syndax Pharmaceuticals (SNDX) Is Down 7.2% After Axatilimab IPF Trial Misses Endpoint Has The Bull Case Changed?
Syndax said its MAXPIRe Phase 2 trial of axatilimab in idiopathic pulmonary fibrosis failed to meet its primary endpoint of slowing lung function decline, so it will halt further IPF development for the drug while other trials continue. Safety in IPF was comparable to placebo, and ongoing studies and the approved chronic GVHD use of Niktimvo are unaffected. The article views the setback as a narrowing of axatilimab's opportunity rather than a franchise-level issue, with Revuforj and Niktimvo still the core commercial pillars. However, Syndax remains loss-making and spends roughly US$400 million a year on R&D and SG&A, so revenue growth is the key factor to watch.
- Could Axsome Therapeutics Turn $5,000 Into $50,000 by 2035?
Axsome Therapeutics (AXSM) has recorded a 29.06% compound annual growth rate over the past five years, and the article notes that sustaining that pace for nine more years would turn $5,000 into $49,670. The company's growth since 2021 has been driven largely by clinical and regulatory progress, including Auvelity, which treats depression and agitation associated with Alzheimer's disease, an indication the article calls fresh in a large market with few approved options. Axsome may earn approval for AXS-12, a treatment for cataplexy associated with narcolepsy, by May 2027, and it has several Phase 3 programs. With a $7.5 billion market cap, the same growth rate over nine years would imply a $74.5 billion company, which the author says would require near-flawless execution and significant commercial penetration. The author judges this highly unlikely, though considers the company's prospects attractive and says it could again beat the market over the long run.
- ORIC Pharmaceuticals (ORIC) Stock Sees Modest Fair Value Lift On Trial Catalyst Optimism
The modeled fair value for ORIC Pharmaceuticals moved from US$20.67 to US$21.93, a small change tied to analyst views on enozertinib and rinzimetostat. Several firms, including Stifel, JPMorgan and H.C. Wainwright, raised price targets into a US$18 to US$27 range, with JPMorgan describing enozertinib as an underappreciated driver. BTIG and Leerink initiated coverage with US$26 targets, while one analyst noted the stock was down 5% at US$12.89 in morning trading on the day of the lung cancer data update. The fair value model also changed the net profit margin assumption from 17.25% to 15.91% and the future P/E from 753.08x to 971.94x.
- argenx Reports Third Quarter 2026 Financial Results and Provides Business Update
argenx reported third-quarter 2026 global product net sales of VYVGART of $1.7 billion, up 54% year over year and 13% quarter over quarter. Positive Phase 3 ALKIVIA results showed consistent treatment effects in IMNM and dermatomyositis, with an sBLA for IMNM on track for submission by year-end 2026. The company submitted an sBLA for ocular myasthenia gravis to the FDA, and a pediatric gMG sBLA was accepted for priority review with a PDUFA target date in February 2027. Phase 3 EMPASSION topline results for empasiprubart in MMN are expected in December 2026, while FB102 is advancing to Phase 3 in celiac disease. argenx continues to target treating 50,000 patients, securing 10 labeled indications and advancing five candidates into registrational development by 2030.
- Viking Therapeutics Initiates Pivotal Phase 3 Trial: Here's Why Investors Have Reason for Optimism After a Disappointing Phase 2
Viking Therapeutics has started two phase 3 trials, SUNRISE-1 and SUNRISE-2, for the oral form of its weight loss drug VK2735, alongside its ongoing injectable phase 3 trials. Investors had been shaken by the phase 2 oral trial (VENTURE-Oral), where 20% of treated participants discontinued due to adverse events and the stock fell sharply, although efficacy over 13 weeks was good. The author argues the phase 3 design is different: 13% of the phase 2 placebo group also stopped due to adverse events, phase 2 used a more aggressive titration, and phase 3 runs 68 weeks. CEO Brian Lian said that in phase 2 patients took 4 tablets that were fairly large, and phase 3 aims for smaller tablets and fewer of them. Phase 3 doses are also lower, at 27.5 mg, 35 mg and 55 mg, compared with 15 mg to 120 mg in phase 2.
Related markets
Latest news
- FPT Loses VND 120,000 Billion in Market Value Over Chairman Trương Gia Bình's “Rebirth” Performance
FPT shares fell 4.74% to VND 50,200 per share on November 2, their lowest level in three years, and the stock has lost over VND 120,800 billion in market value since early February 2025, even as profit kept growing double digits. Pressure has come from sustained foreign net selling, with over 210 million shares (nearly VND 17,000 billion) sold in the first 10 months of 2026, and concerns that AI could reshape traditional software outsourcing, a worry that also weighs on peers such as Infosys and Accenture. Yet FPT posted record Q3 2026 profit attributable to parent shareholders of VND 2,723 billion, and nine-month profit reached VND 7,778 billion, up 13.3%. Vietcap Securities forecasts FPT's profit growth at an average of 14% a year over 2026–2029, below the 22% recorded in 2021–2024.
- YieldMax® ETFs Announces Distributions on MSST, NVIT, and TEST
YieldMax announced Group 3 distributions for its Performance & Distribution Target 25™ ETFs, with the ex-date and record date of November 3, 2026 and payment on November 4, 2026. The funds seek a 25% target annual income level, which the company says is not a guaranteed yield or total return. Distributions are not guaranteed, may vary significantly or be zero, and may include return of capital, which can reduce NAV and trading price over time.
- Prediction: Netflix Will Begin Paying a Dividend in 2027 and Beat the S&P 500 During the Next Decade
The author predicts Netflix will begin paying a dividend in 2027, after its stock fell 7% over the past five years while the Nasdaq Composite rose 75% and the S&P 500 rose 66%. Revenue and earnings are at record highs but are inflated by a one-time $2.8 billion termination fee from Skydance, and full-year 2026 advertising revenue is now projected at $2.7 billion, down from $3 billion. Netflix bought back 63.9 million shares for $4.8 billion in Q3 2026, its largest quarterly repurchase ever, and has $22.3 billion of authorized buybacks remaining; the author views the size of these buybacks as the best signal a dividend could be coming. Analysts' average estimate is $3.77 in 2027 EPS, up 5.3% from $3.58 in 2026, and the stock trades at 16.4 times projected 2026 earnings versus 18.7 for the S&P 500.
- Medallion reports high-grade drill results at Kundip Mining Centre
Medallion Metals has released final results from its 2026 infill drilling programme at the Gem deposit within the Kundip Mining Centre in Western Australia, where the Ravensthorpe Gold Project is under development. The programme comprised 22 reverse circulation and diamond holes totalling 3,093m across the upper levels, largely confirming earlier high-grade results in zones targeted for early development. Key intercepts included 3m at 17.8 g/t gold and 0.3% copper from 66m, and 2m at 21.3 g/t gold and 0.8% copper from 58m. The company said the results strengthen confidence in the grade, width and geometry of the lodes, and several short-strike lodes were closed off as expected. Project development is progressing, with box-cut excavation at 55% completion, underground development scheduled to start in November 2026, and first underground ore expected in the second quarter of 2027.
- C3 Metals Intersects 64.9 Metres at 3.45% Copper Equivalent, Including 23.3 Metres at 6.64% Copper Equivalent at its Khaleesi Project, Peru - Highest Grade Copper and Gold Mineralization Intersected to Date at Khaleesi
C3 Metals (TSXV: CCCM) intersected 64.9 metres at 3.45% copper equivalent (2.53% copper, 0.87 g/t gold, 11.6 g/t silver) in drill hole KHZ5790-005 at its 100%-owned Khaleesi copper project in southern Peru, including 23.3 metres at 6.64% copper equivalent. The company says these are the highest copper grades encountered to date at Khaleesi, and follow-up drilling is underway to test the geometry, continuity and extent of the high-grade mineralization. Copper equivalent uses three-year trailing average prices for 2023–2025 and assumes 80% metallurgical recovery. All intervals are downhole core lengths, and true thicknesses have not yet been determined.
- Apple's new CEO faces earnings test as rising chip costs cloud outlook
Apple reports quarterly results on Monday evening, the first since John Ternus replaced Tim Cook as CEO in September. According to LSEG estimates reported by Reuters, revenue is expected to rise nearly 11% to $113.39 billion and net profit about 6% to $29.04 billion. iPhone revenue is forecast to grow about 15% to $56.54 billion, slowing from roughly 22% in the previous three months, while services revenue may rise almost 10% to $31.56 billion, its slowest pace in more than three years. Investors will watch Christmas-quarter guidance, sales of the iPhone Duo foldable (on sale from 23 October, after the reporting period, starting at $1,999 in the US) and rising memory-chip costs, with TechInsights estimating memory and storage in the iPhone 18 Pro at about $196, versus roughly $52 in the iPhone 17 Pro.
Get the briefing on Telegram or Zalo
Join the Upside Telegram channel or Zalo group for the Vietnam stocks and gold briefing at 8:00 and 19:00 (Vietnam time) on trading days, plus a weekly wrap on Saturday morning.